niacinamide has been researched along with bosutinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar-Suárez, LE; Barroso-Flores, J; Galindo-Murillo, R | 1 |
| Cortes, J; Lang, F | 1 |
| Brooks, A; Hall, KH; Waller, EK | 1 |
| Abdo, A; Aimone, P; Allepuz, A; Annunziata, M; Apperley, JF; Bédoucha, V; Boquimpani, C; Chaudhri, N; Chee, L; Cortes, JE; Fogliatto, LM; García-Gutiérrez, V; Hochhaus, A; Hughes, TP; Kim, DDH; Kim, DW; le Coutre, P; Lomaia, E; Mauro, MJ; Minami, Y; Quenet, S; Réa, D; Sasaki, K; Saussele, S; Turkina, A; Voloshin, S | 1 |
1 review(s) available for niacinamide and bosutinib
| Article | Year |
|---|---|
Third-line therapy for chronic myeloid leukemia: current status and future directions.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Homoharringtonine; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Quinolines | 2021 |
1 trial(s) available for niacinamide and bosutinib
| Article | Year |
|---|---|
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Niacinamide; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Treatment Outcome; Young Adult | 2021 |
2 other study(ies) available for niacinamide and bosutinib
| Article | Year |
|---|---|
A mixed DFT-MD methodology for the in silico development of drug releasing macrocycles. Calix and thia-calix[N]arenes as carriers for Bosutinib and Sorafenib.
Topics: Aniline Compounds; Calixarenes; Computer Simulation; Drug Carriers; Drug Liberation; Molecular Dynamics Simulation; Molecular Structure; Niacinamide; Nitriles; Phenylurea Compounds; Quantum Theory; Quinolines; Sorafenib | 2016 |
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Topics: Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Quinolines | 2021 |